Extranuclear ERα is associated with regression of T47D PKCα-overexpressing, tamoxifen-resistant breast cancer by Perez White, Bethany et al.
 
Extranuclear ERα is associated with regression of T47D PKCα-
overexpressing, tamoxifen-resistant breast cancer
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Perez White, Bethany, Mary Ellen Molloy, Huiping Zhao, Yiyun
Zhang, and Debra A Tonetti. 2013. Extranuclear erα is
associated with regression of t47d pkcα-overexpressing,
tamoxifen-resistant breast cancer. Molecular Cancer 12: 34.
Published Version doi:10.1186/1476-4598-12-34
Accessed February 19, 2015 12:07:52 PM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:11179050
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-
of-use#LAAExtranuclear ERα is associated with regression of
T47D PKCα-overexpressing, tamoxifen-resistant
breast cancer
Perez White et al.
Perez White et al. Molecular Cancer 2013, 12:34
http://www.molecular-cancer.com/content/12/1/34RESEARCH Open Access
Extranuclear ERα is associated with regression of
T47D PKCα-overexpressing, tamoxifen-resistant
breast cancer
Bethany Perez White
1†, Mary Ellen Molloy
1†, Huiping Zhao
1, Yiyun Zhang
2 and Debra A Tonetti
1*
Abstract
Background: Prior to the introduction of tamoxifen, high dose estradiol was used to treat breast cancer patients with
similar efficacy as tamoxifen, albeit with some undesirable side effects. There is renewed interest to utilize estradiol to
treat endocrine resistant breast cancers, especially since findings from several preclinical models and clinical trials
indicate that estradiol may be a rational second-line therapy in patients exhibiting resistance to tamoxifen and/or
aromatase inhibitors. We and others reported that breast cancer patients bearing protein kinase C alpha (PKCα)-
expressing tumors exhibit endocrine resistance and tumor aggressiveness. Our T47D:A18/PKCα preclinical model is
tamoxifen-resistant, hormone-independent, yet is inhibited by 17β-estradiol (E2) in vivo. We previously reported that
E2-induced T47D:A18/PKCα tumor regression requires extranuclear ERα and interaction with the extracellular matrix.
Methods: T47D:A18/PKCα cells were grown in vitro using two-dimensional (2D) cell culture, three-dimensional (3D)
Matrigel and in vivo by establishing xenografts in athymic mice. Immunofluoresence confocal microscopy and co-
localization were applied to determine estrogen receptor alpha (ERα) subcellular localization. Co-immunoprecipitation
and western blot were used to examine interaction of ERα with caveolin-1.
Results: We report that although T47D:A18/PKCα cells are cross-resistant to raloxifene in cell culture and in Matrigel,
raloxifene induces regression of tamoxifen-resistant tumors. ERα rapidly translocates to extranuclear sites during T47D:
A18/PKCα tumor regression in response to both raloxifene and E2, whereas ERα is primarily localized in the nucleus in
proliferating tumors. E2 treatment induced complete tumor regression whereas cessation of raloxifene treatment
resulted in tumor regrowth accompanied by re-localization of ERα to the nucleus. T47D:A18/neo tumors that do not
overexpress PKCα maintain ERα in the nucleus during tamoxifen-mediated regression. An association between ERα and
caveolin-1 increases in tumors regressing in response to E2.
Conclusions: Extranuclear ERα plays a role in the regression of PKCα-overexpressing tamoxifen-resistant tumors. These
studies underline the unique role of extranuclear ERα in E2- and raloxifene-induced tumor regression that may have
implications for treatment of endocrine-resistant PKCα-expressing tumors encountered in the clinic.
Keywords: Breast cancer, PKCα,E x t r a n u c l e a rE R α, Tamoxifen, Raloxifene
Introduction
Patients with estrogen receptor α (ERα)-positive breast
cancer are candidates for treatment with endocrine ther-
apies such as the selective estrogen receptor modulator
(SERM) tamoxifen (TAM), aromatase inhibitors (AIs)
letrozole, anastrozole, or exemestane or the selective
estrogen receptor downregulator (SERD), fulvestrant.
However, both de novo and acquired endocrine resistance
represent a significant clinical problem. Mechanisms of
endocrine resistance include activation of growth factor
signaling and downstream pathway activation including
phosphatidyl inositol 3-kinase (PI3K) and mitogen acti-
vated protein kinase (MAPK) (reviewed in [1]). Numerous
reports from our laboratory and others suggest that activa-
tion of protein kinase C (PKC) signaling, specifically PKCα,
is associated with endocrine resistance in the clinic [2-4].
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TAM-resistant model where PKCα is stably overexpressed
in the T47D:A18 breast cancer cell line [5]. Under two-
dimensional (2D) culture conditions, T47D:A18/PKCα cells
exhibit both TAM-resistance and hormone-independence
characterized by proliferation in the presence and absence
of 17β-estradiol (E2). Paradoxically when T47D:A18/PKCα
cells are grown in vivo as xenograft tumors, E2 adminis-
tration inhibits tumor growth and induces complete tumor
regression in established tumors [6,7]. Similarly, we previ-
ously reported that the MCF-7 TAM tumor model that
exhibits the E2-inhibitory phenotype [8] also overexpresses
PKCα [7]. Previous mechanistic studies in our labora-
tory determined that E2-induced T47D:A18/PKCα tumor
regression is dependent upon ERα,i n c r e a s e dF a s / F a s L –
mediated apoptosis and decreased AKT signaling [9].
Moreover, we showed that T47D:A18/PKCα cultured in
three-dimensional (3D) Matrigel
™ partially recapitulated
the in vivo E2-inhibitory effects by inhibiting colony for-
mation. Further, the membrane impermeable E2-BSA con-
jugate was shown to inhibit T47D:A18/PKCα colony
formation in a manner similar to E2, suggesting the poten-
tial involvement of a plasma membrane localized ERα [9].
In addition to genomic signaling by nuclear ERα, ex-
amples of nongenomic rapid responses of extranuclear
ERα in the presence of E2 are abundant in the literature
[10-14]. Extranuclear ERα plays an important role in cell
proliferation, cell cycle regulation and blockade of cell
death by activating MAPK [15,16] and the AKT signaling
pathways [17-19] in breast cancer cell lines. There is
evidence that extranuclear ERα interacts with several
growth factor receptors as a mechanism for endocrine-
resistant breast cancer by promoting downstream prolif-
eration and survival signals [20-22].
In the present study we determined that in 2D and 3D
cell culture, TAM-resistant T47D:A18/PKCα cells exhibit
cross-resistance to raloxifene (RAL). Similar to the para-
doxical effects of E2 in this model, RAL induces T47D:
A18/PKCα tumor regression. Based on our previous find-
ings showing the dependence of ERα in tumor regression
and the involvement of extranuclear ERα in colony in-
hibition, in this study we determined the subcellular
localization of ERα in T47D:A18/PKCα tumors during re-
gression (E2 and RAL) and during proliferation (absence
or presence of TAM) using immunofluorescence (IF) con-
focal microscopy. Interestingly, ERα localizes to the nu-
cleus in tumors proliferating in a hormone-independent
manner or in mice treated with TAM, whereas ERα local-
izes to extranuclear sites in tumors undergoing regression
with either E2 or RAL. Withdrawal of RAL treatment re-
sults in the resumption of T47D:A18/PKCα tumor growth
accompanied by relocalization of ERα back into the nu-
cleus. We further report an association of extranuclear
ERα with caveolin-1 suggesting a mechanism whereby
ERα may influence growth factor signaling. These findings
are in agreement with our previous report that E2-induced
tumor regression is accompanied by downregulation of
AKT signaling in this model [9]. To our knowledge this is
the first study to report an association of extranuclear ERα
with tumor regression, as opposed to the activation of
growth factor receptor signaling. With the renewed inter-
est in the use of E2 for treatment of endocrine resistant
breast cancer [23,24], our model offers a potential inhibi-
tory mechanism involving extranuclear ERα.
Results
RAL exerts opposite proliferative effects on T47D:A18/
PKCα in vitro and in vivo
We previously reported that overexpression of PKCα
in T47D:A18 cells (T47D:A18/PKCα) results in TAM-
resistant and hormone-independent cell growth in 2D
culture. When xenografts are established from these cells,
tumors are growth-inhibited and completely regress in the
presence of E2 [7]. To determine whether these cells also
exhibit cross-resistance to RAL, a DNA assay in 2D culture
was performed. Whereas the parental T47D:A18/neo
cells are E2-dependent and growth inhibited by both
4-hydroxytamoxifen (4-OHT) and RAL (Figure 1A), the
TAM-resistant T47D:A18/PKCα cells exhibit cross-
resistance to RAL (Figure 1B). When cultured in 3D
Matrigel
™, T47D:A18/PKCα colony formation is inhibited
by E2 as previously reported [9] but grew in the presence
of both 4-OHT and RAL (Figure 1C,D). Therefore T47D:
A18/PKCα cells display similar cross-resistance to 4-OHT
and RAL in 2D and 3D culture.
To examine whether T47D:A18/PKCα cells are similarly
resistant to RAL in vivo, we bilaterally injected T47D:A18/
PKCα cells into the mammary fat pads of ovariectomized
athymic mice and began treatment with TAM (1.5 mg/
day), low dose RAL (0.5 mg/day) or high dose RAL (1.5
mg/day) (Figure 2A). As expected, T47D:A18/PKCα tu-
mors are TAM-resistant as previously described [7] com-
pared to the TAM and RAL-sensitive T47D:A18/neo
tumors (Figure 2C). However, mice receiving the lower
dose of RAL (0.5 mg/day), experienced tumor growth until
week 5, followed by tumor stabilization and partial regres-
sion. Mice receiving the higher dose of RAL (1.5 mg/day)
exhibited minimal tumor growth and achieved tumor
stabilization by week 3 followed by tumor regression after
10 weeks of treatment (Figure 2A). These results indicate
that (1) RAL is capable of inhibiting the growth of T47D:
A18/PKCα TAM-resistant tumors and (2) RAL exerts
contradictory in vitro and in vivo growth effects on T47D:
A18/PKCα cells in a manner similar to E2. The distinction
between E2 and RAL activity is that E2 but not RAL in-
hibits colony formation in 3D culture (Figure 1C, D) [9].
To more closely parallel the clinical situation where
TAM is given to patients for 5 years, we created the
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ging T47D:A18/PKCα tumors in mice treated with 1.5 mg
TAM 5 days/week for 5 years. We then asked whether RAL
was capable of causing tumor regression in this LT-TAM
tumor model. LT-TAM tumors were established and groups
were treated with either 1.5 mg TAM or 1.5 mg RAL per
day. During the first 7 weeks of treatment, both the TAM
and RAL groups exhibited similar tumor growth. However
between weeks 8–10, tumors in the RAL treated group
began to regress (Figure 2B). These results suggest that
RAL is a potential lead compound as an alternative to E2
for second-line treatment following tumor progression on
TAM in those tumors that overexpress PKCα.
E2 and RAL induce ERα translocation from the nucleus to
extranuclear sites in vivo
We previously reported that ERα and the extracellular
matrix (ECM) are required for T47D:A18/PKCα tumor
regression and that plasma membrane-associated ERα
is likely to mediate the inhibitory effects of E2 [9]. To
test our hypothesis that extranuclear ERα participates
in E2-induced T47D:A18/PKCα tumor regression, we
asked whether ERα localization differs in E2 and RAL-
induced T47D:A18/PKCα regressing tumors compared
with TAM-stimulated T47D:A18/PKCα tumors or E2-
stimulated T47D:A18/neo tumors. To address this ques-
tion, we established T47D:A18/neo and T47D:A18/PKCα
tumors in athymic mice (Figures 3A-3D) and as previously
reported, T47D:A18/neo tumors are stimulated by E2
(Figure 3A) and are TAM and RAL-sensitive (Figure 2C),
whereas T47D:A18/PKCα tumors are TAM-resistant and
hormone-independent (Figure 3B) and regress following
E2 treatment (Figures 3C and 3D) [7]. As we report here
for the first time, RAL induces T47D:A18/PKCα tumor
regression, although the degree of regression with RAL is
not as complete as is seen with E2 (Figure 3C). Upon
withdrawal of RAL, we observed re-growth of T47D:A18/
PKCα tumors. In contrast, no resumption of tumor
growth is seen upon discontinuation of E2 treatment for
up to 31 weeks (Figure 3D). Since the E2 capsules main-
tain constant serum E2 levels for only 8–10 weeks, we are
confident that the E2 capsule is depleted by week 20 and
have confirmed no detectable serum E2 by mass spec-
trometry at 31 weeks (data not shown).
IF confocal microscopy of T47D:A18/neo E2-stimulated
tumors and TAM- and RAL-regressing tumors illustrates
that ERα is mainly localized in the nucleus (Figure 4A).
The T47D:A18/neo no treatment (NT) group is not avail-
able for comparison since T47D:A18/neo cells required E2
for tumor growth. Similarly, ERα is located within the
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Figure 1 T47D:A18/PKCα cells are resistant to 4-OHT and RAL in 2D and 3D cell culture. DNA and Matrigel
™ colony formation assays were
performed as described in materials and methods. Cells were grown in the presence of vehicle (DMSO, 0.1%), E2 (10
-9M), 4-OHT (10
-7M) or RAL (10
-7M)
with media changes every three days. A. T47D:A18/neo cells. B. T47D:A18/PKCα cells. RFU, relative fluorescence units. C. Quantification of T47D:A18/
PKCα colonies. Graphs are representative of at least three independent experiments and error bars represent SEM. *P<0.05 compared to vehicle; by
one-way ANOVA followed by Bonferroni’s post-test. D. Photographic representation of T47D:A18/PKCα colonies. Total magnification: 6X.
Perez White et al. Molecular Cancer 2013, 12:34 Page 3 of 13
http://www.molecular-cancer.com/content/12/1/34nucleus in T47D:A18/PKCα NT and TAM treatment
groups. However, ERα is almost completely localized to
extranuclear sites in E2- and RAL-induced regressing
T47D:A18/PKCα tumors. Interestingly, following with-
drawal of RAL (RAL W/D) tumors resume growth and
ERα re-localizes to the nucleus. Semi-quantitative analysis
of ERα signals from tumor sections showed a significant
re-localization from the nucleus to the cytoplasm in E2-
and RAL-treated T47D:A18/PKCα tumors compared to
NT, TAM or RAL W/D (Figure 4B). ERα translocation to
extranuclear sites by E2 was verified with the 1D5 ERα
antibody directed towards a different epitope of ERα
(Additional file 1). ERα protein levels from each tumor
group were also assessed by western blot (Figure 4C). As
previously reported, ERα protein expression is elevated in
T47D:A18/PKCα tumors even though ER function as de-
termined by ERE-luciferase activity is decreased [5]. The
abundance of ERα protein as assessed by western blot is
in agreement with the IF image ERα signal intensity
(Figures 4A,C). The observed downregulation of ERα pro-
tein by E2 and ERα stabilization by antiestrogens is consid-
ered classic ERα regulation as previously established [25-28].
Therefore TAM and RAL which oppositely regulate
T47D:A18/PKCα tumor growth, induces differential ERα
subcellular localization. Furthermore, T47D:A18/PKCα
tumor regression induced by either E2 or RAL is associ-
ated with extranuclear ERα. The finding that ERα is lo-
calized to the nucleus during RAL and TAM-induced
T47D:A18/neo tumor regression suggests that it is not
simply regression that triggers ERα to exit from the nu-
cleus, but localization may be influenced by PKCα
overexpression.
Association of ERα with caveolin-1
ERα does not have a membrane localization sequence
thus it does not behave like a transmembrane receptor
[29]. Membrane ERα normally exists as a cytoplasmic
pool and can be tied to the inner face of the plasma
membrane bilayer through binding to the lipid raft pro-
tein caveolin-1 [30,31]. To determine whether there is a
direct physical interaction between ERα and caveolin-1,
we prepared total protein extract from tumors and per-
formed co-immunoprecipitation (co-IP) using an ERα
antibody followed by western blot analysis (Figure 5A).
As expected, the level of total ERα was lower in tumors
from the E2 treatment group. However, immunodetec-
tion with a caveolin-1 antibody showed a significant in-
crease in complex formation between ERα and caveolin-1
in T47D:A18/PKCα tumors from the E2 treatment group
compared with the T47D:A18/PKCα NT group and the
T47D:A18/neo E2 group (Figure 5B). These results indi-
cate that the abundance of the ERα/caveolin-1 complex is
increased in response to E2, but not from treatment with
TAM or RAL. We conclude that ERα/caveolin-1 complex
A
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Figure 2 RAL inhibits TAM-resistant T47D:A18/PKCα xenograft
tumors. Xenograft tumors were formed as described in materials
and methods. Treatments for TAM and RAL were given by oral
gavage 5 days/week. A. T47D:A18/PKCα tumors. Mice (10/group)
were given TAM (1.5 mg/day) or RAL (0.5 mg/day or 1.5 mg/day).
B. LT-TAM-treated T47D:A18/PKCα tumors. Mice (10/group) received
TAM (1.5 mg/day) or RAL (1.5 mg/day). C. T47D:A18/neo tumors.
Mice (6/group) were given no treatment, E2 capsule (1.0 cm), TAM
(1.5 mg/day) or RAL (1.5 mg/day). The dotted line indicates initiation
of TAM or RAL treatment following 8 weeks of E2 treatment. Error
bars represent SEM.
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duced with E2, but not with transient tumor regression as
observed with RAL, nor with proliferating T47D:A18/
PKCα tumors (NT, TAM, RAL W/D). This result is
consistent with the hypothesis that E2-induced tumor
regression is accompanied by ERα exit from the nucleus
and association at the plasma membrane, perhaps via
caveolin-1.
ERα localization in the 2D and 3D microenvironment
As previously described [9], the ECM is required for the
growth inhibitory effect of E2 on T47D:A18/PKCα cells;
E2 stimulates T47D:A18/PKCα cells proliferation on 2D
cell culture, yet E2 inhibits colony formation in 3D
Matrigel
™. However we report here that T47D:A18/
PKCα cells are resistant to RAL both on 2D and 3D
(Figures 1B, C), yet RAL inhibits tumor growth (Figure 2).
Therefore we wanted to determine whether extranuclear
ERα correlates with inhibition of growth (on 2D and 3D)
and/or colony regression. Inhibition of colony formation
by E2 in 3D culture is analogous to the in vivo phenotype
whereby E2 prevents tumor establishment [7]. However,
unlike the in vivo phenotype, E2 is incapable of initiating
regression of an established T47D:A18/PKCα colony in
Matrigel
™. To determine whether extranuclear ERα is a
response to E2 and RAL treatment in 3D culture or
whether ERα translocation occurs only during regression
in tumors, we compared ERα subcellular localization in
T47D:A18/neo and T47D:A18/PKCα cells grown in 2D
and 3D culture. In 2D culture ERα is both nuclear and
cytoplasmic in T47D:A18/neo cells, whereas ERα is
mainly nuclear in T47D:A18/PKCα cells following 1 h
exposure to E2, 4-OHT or RAL (Additional file 2).
These results indicate that ERα localization does not
change in T47D:A18/neo and T47D:A18/PKCα follow-
ing 1 h treatment in 2D culture.
To address ERα localization in 3D culture, T47D:A18/
neo and T47D:A18/PKCα cells were plated in Matrigel
™
under two treatment paradigms. The first paradigm is
known to inhibit colony formation in the presence of
E2 where cells are plated (as shown in Figure 1C, D) and
given continuous treatment for 6 days with media changes
every third day. Under these conditions, T47D:A18/neo
cells in colonies showed nuclear ERα expression in the E2
treatment group and no expression in vehicle control, 4-
OHT or RAL groups and T47D:A18/PKCα colonies had
cells with nuclear ERα expression in all groups (Additional
file 3). These results indicate that ERα subcellular lo-
calization does not change as a result of continuous treat-
ments in 3D culture (Additional file 3).
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Figure 3 Growth of T47D:A18/neo and T47D:A18/PKCα xenograft tumors. Xenograft tumors were formed as described in materials and
methods. A. T47D:A18/neo tumors (NT, 15 mice/group and E2, 3 mice/group). B. T47D:A18/PKCα tumors (10 mice/group). C. T47D:A18/PKCα
tumors. Tumors were grown to an average size of 0.5 cm
2. Mice were then randomized into NT, RAL or E2 groups (large arrow, 9 mice/group).
Two weeks later RAL treatment was stopped (small arrow). D. T47D:A18/PKCα tumors (5 mice/group). Tumors were grown to an average size of
0.3 cm
2. Mice were then randomized into NT or E2 groups (arrow).
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gression. Colonies were allowed to establish for 10 days
when treatments were initiated and continued for either
24 h or 10 days with E2, 4-OHT or RAL. In contrast to
E2-induced tumor regression seen in vivo,t r e a t i n gc o l -
onies does not cause a decrease in colony number or size
(data not shown). Following 24 h treatment of established
T47D:A18/neo colonies, there was no ERα expression in
the vehicle and E2 treatment groups and sparse staining
in the 4-OHT and RAL groups (Additional file 4). Exam-
ination of T47D:A18/PKCα colonies under the same con-
ditions, shows strong ERα nuclear staining in the vehicle,
4-OHT and RAL treated groups. However, in the 24 h E2
treatment group, some colonies showed nuclear staining
while other colonies showed membrane and/or cytoplas-
mic staining (Additional file 4). To determine if treating
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Figure 4 ERα localizes to extranuclear sites in E2- and RAL-induced T47D:A18/PKCα regressing tumors. A. Tissue sections were
immunostained as described in materials and methods. Images are representative photographs of immunostained tumor sections. Sections were
costained for ERα (green) and nuclei (blue). Scale bar= 20 μm. All images were acquired and processed using parameters described in materials
and methods. PKCα, T47D:A18/PKCα; neo, T47D:A18/neo. B. Quantification of ERα localization in tumor sections. At least three fields from each
tumor were counted. T47D:A18/neo is represented by two individual tumors. Bars representing T47D:A18/PKCα tumors show the mean (± SEM)
of three individual tumors. ***, P<0.001 compared to PKCα NT, TAM and RAL W/D by two-way ANOVA. C. Expression of ERα in whole cell tumor
lysates. Molecular weights of ERα and β-actin are 67 kDa and 42 kDa, respectively. Values represent β-actin-normalized ERα expression relative to
T47D:A18/neo E2-treated tumors.
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complete translocation of ERα from the nucleus to the
cytoplasm, we extended treatment for 10 days with media
changes every three days before IF staining. Under these
conditions, ERα is localized to the nucleus in all groups
of T47D:A18/neo colonies as well as T47D:A18/PKCα
vehicle control, 4-OHT and RAL groups (Figure 6). How-
ever, ERα is completely extranuclear in all cells growing in
response to E2. Taken together these findings suggest that
ERα localization does not correlate with proliferative re-
sponse in 2D cell culture nor with inhibition of colony for-
mation in 3D Matrigel
™. However, under conditions that
mimic tumor regression, T47D:A18/PKCα colonies ex-
hibit complete ERα translocation out of the nucleus in re-
sponse to E2 after 10 days and this effect is seen as early
as 24 h. While E2 administration to established colonies
in Matrigel
™ induces ERα translocation to extranuclear
sites, ERα translocation alone is not sufficient to induce
regression likely due to the requirement of additional fac-
tors found in the tumor microenvironment, but not in
Matrigel
™. We also find E2 and RAL exert opposite ef-
fects on ERα localization in T47D:A18/PKCα cells plated
in 3D Matrigel
™, but similar localization in vivo.
Discussion
In this paper we have shown by IF confocal microscopy
that ERα translocates from the nucleus to the extranu-
clear space upon E2 and RAL-induced tumor regression
in our T47D:A18/PKCα preclinical TAM-resistant model.
This model is clinically relevant as evidenced by the
reported success of E2 in the clinic [23,24]. We initially as-
sociated PKCα expression with TAM resistance [2], and
others further identified PKCα as a marker of endocrine re-
sistance and breast cancer aggressiveness [3,4]. Extranuclear
ERα was previously reported to play a role in endocrine-
resistant breast cancers specifically by interacting with
growth factor receptors to activate proliferative and pro-
survival signals [20-22]. However we demonstrate here
that ERα translocation is associated with tumor regression
only in PKCα overexpressing tumors in response to E2
and RAL. Our findings imply that a specific subset of
endocrine-resistant breast cancers that express PKCα may
be uniquely susceptible to E2 therapy. Although the litera-
ture is conflicting regarding the level of PKCα expression in
breast cancers compared to the normal breast [32-36], vari-
ability in PKCα expression amongst breast cancers and the
link to endocrine resistance and tumor aggressiveness is
clear. Based on three reports in the literature, the preva-
lence of PKCα expression in all breast cancers ranges be-
tween 28% to as high as 70% [3,4,37]. Even if the lowest
estimate of 28% prevalence is the most accurate, this still
represents a significant number of patients that may benefit
from E2 treatment.
There are numerous reports of nongenomic signaling
by estrogen in breast cancer cell lines [38,39] and there
is evidence that this pathway is upregulated in endocrine
resistant breast cancers. Translocation of nuclear ERα to
extranuclear sites is reported to be involved in cytoskel-
etal remodeling, migration and invasion [40] and re-
cently shown to play an important role in breast cancer
cell motility and metastasis [41]. High expression of the
MTA1 protein is reported to sequester ERα in the cyto-
plasm and activate MAPK signaling [42], and the same
group reported that overexpression of Her-2 causes ERα
nuclear to cytoplasmic translocation [43]. Fan et al. [44]
showed that long term exposure to TAM causes trans-
location of ERα from the nucleus to the cytoplasm and
enhances the interaction between ERα and EGFR. All of
these examples in the literature describe the activation
of signaling pathways by extranuclear ERα leading to
cancer cell proliferation and survival. However in our
study, we present a novel finding that translocation of ERα
from the nucleus to extranuclear sites occurs following
E2- and RAL-induced T47D:A18/PKCα tumor regression.
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Figure 5 ERα/caveolin-1 complex formation in response to E2,
TAM and RAL treatment in T47D:A18/PKCα tumors. A.
Representative western blot of co-IP experiments in T47D:A18/PKCα
and T47D:A18/neo tumor extracts as detailed in materials and
methods. B. Densitometric quantification of three co-IP experiments
from three independent tumors for each group. Error bars represent
SEM. *, P<0.05 compared to all groups determined by one-way
ANOVA followed by Bonferroni’s post-test.
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companied by apoptosis mediated in part by Fas/FasL and
downregulation of the AKT pathway [9]. An additional
novel finding is that TAM and RAL elicit opposite growth
effects in our T47D:A18/PKCα tumor model. We
hypothesize that PKCα, a cytoplasmic protein that translo-
cates to the plasma membrane when activated [45], may
physically interact with other growth factor receptors and
signaling pathways [46]. A recent publication by Guttierez
et al. shows that translocation of ERα to the plasma mem-
brane in response to E2 results in activation of PKCα/ERK
1/2 signaling in anterior pituitary cells, yet PKCα is not re-
sponsible for mediating the physical translocation of ERα
to the plasma membrane [47]. Src kinase is one of the im-
portant molecules of the signalosome complex which plays
a critical role in E2-mediated nongenomic signaling [48].
It has been reported in the literature that Her-2
upregulates and activates PKCα through src kinase in Her-
2 mediated cancer cell invasion [49]. Longo et al.h a s
shown that a PKCα-src kinase-ERα interaction is critical
in the modulation of estrogen responsiveness and the dif-
ferentiation process in osteoblasts [50]. However, we were
unable to detect a physical interaction between PKCα and
ERα, Her2 or src in our tumor model.
We detected a physical interaction between ERα and
caveolin-1 by co-IP (Figures 5A-B). These results suggest
neo PKCα
ERα
β-Actin
PKCα
4-OHT
PKCα
Vehicle
neo
E2
PKCα
RAL
PKCα
E2
neo
4-OHT
neo
RAL
neo
Vehicle
ERα DAPI Merge AB
1.0 1.22 1.43 1.29 5.11 0.87 3.19 3.24
Figure 6 E2 induces complete relocalization of ERα in established T47D:A18/PKCα colonies after 10 days. A. T47D:A18/neo colonies (neo)
and T47D:A18/PKCα colonies (PKCα) colonies were immunostained for ERα (green) and nuclei (blue). All images were acquired and processed
using parameters described in materials and methods. Colonies were grown for 10 days then treated for 10 days with vehicle (EtOH, 0.1%), E2
(10
-9 M), 4-OHT (10
-7 M) or RAL (10
-7M). Scale bar= 20 μm. B. Expression of ERα in whole cell colony lysates. Molecular weights of ERα and β-actin
are 67 kDa and 42 kDa, respectively. Values represent β-actin-normalized ERα expression relative to T47D:A18/neo E2-treated colonies.
Perez White et al. Molecular Cancer 2013, 12:34 Page 8 of 13
http://www.molecular-cancer.com/content/12/1/34that caveolin-1 may be responsible for transporting ERα
to the plasma membrane during E2-induced tumor re-
gression. Palmitoylation of ERα is known to be necessary
for the physical association with caveolin-1 and in particu-
lar palmitoylation of the E domain of ERα at C447 along
with nine flanking amino acids are required for association
with caveolin-1 [30,31,51,52]. The ERα-caveolin-1 complex
in turn facilitates the translocation of the caveolae rafts to
the plasma membrane. Caveolin-1 serves as a scaffold pro-
tein at the membrane in the recruitment of signaling mole-
cules to form a signalosome complex that can include
ERα. Taken together these results suggest that perhaps
PKCα is capable of modifying the interaction of ERα and
caveolin-1, potentially at the membrane via the proposed
signalosome to effect tumor regression. It is interesting to
note that ERα/caveolin-1 complex formation correlates
with durable tumor regression produced with E2, but not
with transient tumor regression as observed with RAL, nor
with proliferating T47D:A18/PKCα tumors (NT, TAM,
RAL W/D). Although ERα translocation to extranuclear
sites does occur in Matrigel
™ in response to E2 (Figure 6),
colony regression is not initiated perhaps because a com-
ponent in the tumor microenvironment is also required to
initiate the regression signal. As shown in Figures 3C-D,
E2-induced tumor regression occurs rapidly and tumors
a r eg o n ew i t h i n2 –3 weeks. Matrigel
™ results reveal
that the translocation of ERα may be an early event as ERα
was seen in the membrane and cytoplasm in some colonies
at 24 h further illustrating a rapid response to E2 treat-
ment. Our results regarding ERα translocation in the
Matrigel
™ environment compared with in vivo tumors
highlight the importance of the ECM in triggering tumor
regression.
Since we and others have reported that PKCα expres-
sion can be a predictive marker of TAM resistance [2-4]
our T47D:A18/PKCα model suggests that detection of
extranuclear ERα can be used to monitor therapeutic re-
sponse in TAM-resistant, PKCα-expressing breast can-
cers. Unfortunately, extranuclear ERα is not currently
measured clinically and although pathologists may ob-
serve such staining, it is not reported. A recent report
by Welsh et al. [53] with the purpose of testing a panel
of ERα-specific antibodies to detect non-nuclear ERα
in clinical specimens found the average incidence to be
only 1.5%. In an accompanying commentary, Levin
points out that while it is possible that the number of
breast tumors that express extranuclear ERα may indeed
be small, it is also possible that more sensitive tech-
niques are required to detect the very small ERα pools
located outside of the nucleus [54]. We offer the possi-
bility that extranuclear ERα may be detected more fre-
quently in PKCα-expressing tumors that are regressing
possibly indicating a response to treatment. It remains
to be seen whether other techniques will be developed
that may improve the detection of extranuclear ERα in
clinical specimens.
We have previously suggested that PKCα may be used
as predictive biomarker for the use of E2 or an E2-like
compound to effect tumor regression [9], and in fact the
utility of using E2 was demonstrated [23]. We report
here that not only E2, but RAL is capable of eliciting
T47D:A18/PKCα tumor regression, despite the fact that
these tumors are TAM-resistant. Further we have shown
that following 5 years of TAM treatment, these tumors are
still sensitive to RAL-induced tumor regression (Figure 2B).
Although RAL may be considered as a potential treatment
for patients with PKCα-expressing breast cancers, RAL is
not as durable as E2 to elicit complete tumor regression
(Figure 3D). Since RAL has poor bioavailability, we are cur-
rently testing a series of benzothiophene analogues in our
T47D:A18/PKCα preclinical model for improved tumor in-
hibitory activity.
Conclusions
In summary, we report for the first time the involvement
of extranuclear ERα in an endocrine resistant-tumor
model to be associated with tumor regression and not
growth stimulation. Key to this phenomenon may be ex-
pression of PKCα, frequently associated with endocrine
resistance and a potential biomarker for the use of E2 or
RAL-like compounds for the treatment of endocrine-
resistant breast cancer.
Methods
Reagents
For in vitro experiments dimethylsulfoxide (DMSO),
ethanol, E2, 4-OHT and RAL were obtained from
Sigma-Aldrich (St. Louis, MO USA). For in vivo experi-
ments E2 and TAM were obtained from Sigma. RAL
(Evista
W, Eli Lilly and Company, Indianapolis, IN USA)
was purchased from the University of Illinois at
Chicago Hospital Pharmacy. Cell culture reagents were
obtained from LifeTechnologies (Carlsbad, CA USA). Tis-
sue cultureware was purchased from Becton-Dickinson
(Franklin Lakes, NJ USA). The following antibodies were
used: rabbit monoclonal ERα (for tissue and cells, SP1,
Lab Vision, Thermo Scientific, Kalamazoo, MI USA),
mouse monoclonal ERα (alternative epitope to confirm
specificity for tissue, 1D5, N-terminal epitope, Abcam,
Cambridge, MA USA), rabbit polyclonal ERα (for col-
onies, HC20, Santa Cruz Biotechnology, Santa Cruz, CA
USA), and mouse monoclonal caveolin-1 (Clone2234, BD
Transduction Laboratories, Franklin Lakes, NJ USA). Sec-
ondary antibodies included: anti-rabbit Alexa Fluor 488
(Life Technologies, Carlsbad, CA USA), anti-mouse Cy3
(Jackson Immunoresearch Laboratories, West Grove, PA
USA) and HRP-cojungated anti-rabbit and anti-mouse
(GE Healthcare UK Limited, Buckinghamshire, UK).
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T47D:A18/neo and T47D:A18/PKCα [5] cells were
maintained in RPMI 1640 with phenol red supplemented
with 10% fetal bovine serum (FBS) and G418 (500 μg/ml)
at 37°C, 5% CO2. Prior to experiments cell lines were
placed in phenol red-free RPMI 1640 supplemented with
10% stripped FBS (E2-depleted media) for 3 days and
maintained in the same manner for the duration of experi-
ments. Cell lines were tested for Mycoplasm contamination
on a regular basis (MycoAlert
™ Mycoplasm Detection Kit,
Lonza Ltd., Rockland, ME, USA). Cell lines were not au-
thenticated by the authors.
DNA growth assay
Cells were plated at a density of 15,000 cells/well in 24-
well plates. Treatment media (vehicle, DMSO [0.1%], E2
[10
-9M], 4-OHT [10
-7M] or RAL [10
-7M]) was added
t h ef o l l o w i n gd a y( D a y1 )a n dc h a n g e de v e r yt h r e ed a y s .
Growth was determined by incubating cells with
Hoechst 33342 cell permeable dye (Life Technologies,
Carlsbad, CA USA) for 1 h at 37°C and reading fluor-
escence at excitation 355 nm/emission 460 nm on a
Perkin Elmer Victor
3 V( W a l t h a m ,M AU S A )p l a t e
reader.
Matrigel
™ colony formation assay
Treatments (ethanol [0.1%], E2 [10
-9M], 4-OHT [10
-7M]
or RAL [10
-7M]) were added to liquefied phenol-red free
Matrigel
™ matrix (BD Biosciences, Franklin Lakes, NJ
USA) and used to coat 6-well plates and solidified at 37°C
for 30 min. Cells (5000) were seeded in E2-depleted media
containing treatments on top of pre-gelled Matrigel
™ and
incubated at 37°C with 5% CO2. Treatment media were
changed every three days. Colonies were stained with
0.25% crystal violet (Sigma-Aldrich, St. Louis, MO USA)
solution for 30 min and then destained with 0.9% saline
for 20 min at room temperature. Colony number was de-
termined by counting five 1.0 cm
2 areas.
Xenograft tumor establishment
All procedures involving animals were approved by the
Animal Care and Use Committee of the University of
Illinois at Chicago according to institutional and national
guidelines. T47D:A18/neo and T47D:A18/PKCα tumors
were established in 4–6 week old ovariectomized athymic
nude mice (Harlan Laboratories) as previously described
[7]. LT-TAM tumors were derived by in vivo serial
transplantation in the presence of TAM for 5 years.
Where indicated, mice were given the following treat-
ments as previously described: E2 (1.0 cm silastic cap-
sule, s.c.), TAM (1.5 mg/day, p.o.), RAL (0.5 mg/day,
p.o.), or RAL (1.5 mg/day, p.o.) [55]. Tumor cross-
sectional area was determined at least weekly and some-
times daily using digital calipers and calculated using the
formula: length/2×width/2×π.M i c ew e r ee u t h a n i z e db y
CO2 inhalation and cervical dislocation. Tumors were im-
mediately excised and either fixed in 10% buffered formalin
for paraffin block preparation ors n a pf r o z e ni nl i q u i dn i t r o -
gen and stored at −80°C for co-immunoprecipitation and
western blot analysis.
Tumor IF confocal microscopy and co-localization analysis
Tumors sections (4 μm) were prepared from paraffin
blocks for IF staining by deparaffinization and rehydration.
Antigen retrieval was performed by incubating slides in
Tris-EDTA (pH=9.0) buffer at 90°C and allowed to cool
at room temperature for 45 min. Slides were blocked
with antibody diluent (DAKO, Carpinteria, CA USA) for
20 min followed by primary antibody at 1:100 in antibody
diluent for 1 h at room temperature. Slides were incu-
bated with fluorescence-conjugated secondary antibodies
at 1:100 in antibody diluent for 45 min at room tem-
perature followed by 4’ , 6-diamidino-2-phenylindole (DAPI)
(1 μg/mL), DAKO, Carpinteria, CA USA) for 15 min and
mounted with Vectashield mounting media (Vector La-
boratories, Burlingame, CA USA). Confocal microscopy
was performed with a Zeiss LSM 510 microscope (Carl
Zeiss, Incorporated, North America, Thornwood, NY USA).
The objective used was a C-Apochromat 63X with a nu-
merical aperture of 1.2. Image acquisition scaling was
X: 0.14 μm and Y: 0.14 μm and stack size was X: 142.86 and
Y: 142.86, these two parameters were kept constant across
samples. Pinholes and laser intensities were kept constant
for each wavelength (green: λ=488 nm, laser= 15%, pin-
hole= 228 μma n db l u e :λ=4 0 5 n m , l as er=5 % , p i n h o l e
194 μm) across all samples. Images were modified following
acquisition using the Zeiss LSM Image Browser by similarly
enlarging images 2X and increasing the brightness and con-
trast by 10%.
Co-IP and western blot
Tumors were ground into a fine powder in liquid nitro-
gen and resuspended in cell lysis buffer (20 mM Tris–
HCl [pH 7.5], 150 mM NaCl, 1 mM Na2EDTA, 1 mM
EGTA, 1% Triton X-100, with protease [Sigma, St. Louis,
MO] and phosphatase [Calbiochem, Bilerica, MA] inhibi-
tor cocktails) and homogenized using a Polytron hand-
held homogenizer (Fisher Scientific, Pittsburgh, PA USA).
Protein concentration was determined by the Bradford
method (Bio-Rad Laboratories, Hercules, CA USA). Equal
amounts of total tumor extract (500 μg) were immuno-
precipitated by rotating for 2 hr at 4°C with antibody
followed by overnight rotation with protein-A Dynabeads
(Life Technologies, Carlsbad, CA), at 4°C. Samples were
washed and boiled for 10 min then eluted from beads with
sample buffer containing 2-mercaptoethanol (Sigma, St.
Louis, MO USA). Samples were subjected to 8% SDS-
PAGE, followed by western blot with respective primary
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chemiluminescence using a Chemi Doc Gel Documenta-
tion System (Bio-Rad Laboratories, Hercules, CA USA).
Cell IF microscopy
Cells were seeded in phenol red-containing media onto
Lab-Tek II 4-well chamber slides (Millipore, Billerica,
MA) at a density of 3×10
4 cells/well. The following day
cells were placed in E2-depleted media for 3 days then
given treatment media (DMSO [0.1%], E2 [10
-9M], 4-
OHT [10
-7M] or RAL [10
-7M]). For IF, cells were fixed in
100% methanol overnight at −20°C and stained as de-
scribed above for tissue sections. Cells were imaged using
Zeiss Axiovision Observer D1 microscope (Carl Zeiss,
LLC, Thornwood, NY USA).
Colony IF microscopy
Colonies were formed by ding cells in Matrigel
™ as de-
scribed above and treated with DMSO (0.1%), E2 (10
-9M),
4-OHT (10
-7M) or RAL (10
-7M). Colonies were extracted
from the Matrigel
™ by adding ice-cold PBS-EDTA to the
rinsed and aspirated wells. Gel was lifted from the bottom
of the well with a cell scraper and plates were shaken
gently on ice. Colonies were then transferred to a conical
tube and shaken on ice for an additional 30 min until
Matrigel
™ was completely dissolved, collected by centrifu-
gation at 115g for 2 min and pipetted onto a slide. Slides
were then fixed in ice cold methanol and stored at −80°C
until staining (as described above). Confocal microscopy
was performed with a Zeiss LSM 510 microscope. The ob-
jective used was a C-Apochromat 63X with a numerical
aperture of 1.2. Image acquisition scaling was X: 0.14 μm
and Y: 0.14 μm and stack size was X:142.86 and Y: 142.86,
these two parameters were kept constant across samples.
Pinholes and laser intensities were kept constant for each
wavelength (green: λ=488 nm, laser=10%, pinhole=200
μm and blue: λ=405 nm, laser=13%, pinhole 92 μm)
across all samples. Images were modified following acqui-
sition using the Zeiss LSM Image Browser by similarly en-
larging images 2X and increasing the brightness and
contrast by 10%.
Statistical analysis
The specific statistical test applied to the data is de-
scribed in the figure legends. All of the statistics on the
data were performed using GraphPad Prism 5.02 Soft-
ware (La Jolla, CA USA).
Additional files
Additional file 1: ERα is localized to extranuclear sites in E2-
regressing tumors with an antibody directed to an alternative
epitope. Tissue sections were immunostained as described in materials
and methods. Images are representative photographs of immunostained
tumor sections. Sections were costained for ERα (green) and nuclei (blue).
Scale bar = 20 μm.
Additional file 2: ERα localization does not change in cells grown in
2D culture. T47D:A18/neo (neo) and T47D:A18/PKCα (PKCα) cells were
immunostained for ERα (green) and nuclei (blue) as detailed in materials
and methods. Cells were treated (Vehicle [EtOH 0.1%], E2 [10
-9 M], 4-OHT
[10
-7 M] or RAL [10
-7M]) for 1 h. Scale bar =50 μm.
Additional file 3: Continuous E2 treatment inhibits colony
formation but does not induce extranuclear ERα in T47D:A18/PKCα
cells. T47D:A18/neo colonies (neo) and T47D:A18/PKCα colonies (PKCα)
colonies were immunostained for ERα (green) and nuclei (blue) as
detailed in materials and methods. Colonies were given treatment upon
plating with vehicle (EtOH, 0.1%), E2 (10
-9 M), 4-OHT (10
-7 M) or RAL (10
-
7M) and were treated continuously for 6 days. Scale bar = 20 μm.
Additional file 4: E2 treatment in established T47D:A18/PKCα
colonies induces partial extranuclear ERα following 24 h treatment.
T47D:A18/neo colonies (neo) and T47D:A18/PKCα (PKCα) colonies were
immunostained for ERα (green) and nuclei (blue) as detailed in materials
and methods. Colonies were grown for 10 days then treated for 24 h
with vehicle (EtOH, 0.1%), E2 (10
-9 M), 4-OHT (10
-7 M) or RAL (10
-7M). N:
nuclear, M/C: membrane/cytoplasmic. Scale bar= 20 μm.
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